The Alouette Test in Parkinson Disease

Parkinson Disease Clinical Trial

— REPEAT  

Official title:

Screening for Reading Difficulties in Parkinson's Disease: An Evaluation of the Alouette Test

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03958175
• Other study ID #: REPEAT
• Status: Completed
• Start date: November 1, 2015
• Est. completion date: April 1, 2016

Study information

• Verified date: May 2019
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Reading disorders in Parkinson's Disease (PD) are poorly evaluated due to the lack of validated tests to screen for them. They are often attributed to hand tremors associated with the disease. In this study, the investigating team evaluated the "alouette test" validated for dyslexia screening, in PD by comparing the results to healthy patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 38
• Est. completion date: April 1, 2016
• Est. primary completion date: April 1, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients with Parkinson's Disease

• Montreal Cognitive Assessment (MoCA) test > 20

Exclusion Criteria:

• Patient's with supranuclear Palsy

• Other neurologic disease

• Any ophthalmologic disease

• Presence of a nystagmus

• Visual acuity < 0.6

Related Conditions & MeSH terms

• Parkinson Disease

Intervention

Other:
• Alouette test (reading test)
The alouette test was assessed at a fixed distance of 40 centimeters on a fixed surface to avoid errors related to hand tremors.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Score on the Alouette test	The Alouette test is based on the precision and speed in reading a short text (279 words). The score corresponds to the total number of words correctly read.	1 day